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adjust these estimates to reﬂect baseline levels of information
transmission using data on the baselines rates at which physi-
cians can identify the optimal treatment without any explicit
mechanism to elicit preferences from the patients. Obtaining
data on the baseline levels of information transmission should
be a high priority. The EVSOI approach may also be used to
value direct to consumer advertising and certain educational 
programs for patients that aim to promote optimal health 
decisions.
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OBJECTIVE: The contingent valuation (CV) method is increas-
ingly employed within the health care sector (HCS); however, the
extent to which hypothetical choices mimic real economic
choices remains unclear. A few previous experiments have
studied the correspondence between hypothetical and real will-
ingness to pay (WTP) within the HCS. The ﬁndings suggest that
hypothetical bias (HB) (i.e. overestimation of real WTP) exists
in the HCS, just as it does outside of the HCS. An important
area of research is whether or not HB can be “calibrated” so
that hypothetical choices more closely mimic real economic
choices. We conducted an experiment directly comparing
responses to a dichotomous choice CV question with real pur-
chase decisions using a pharmacist provided diabetes manage-
ment service as the item valued. We examine whether HB exists
and we evaluate the usefulness of two HB mitigation techniques:
the “certainty approach” and the “cheap-talk approach”.
METHODS: A CV survey using 267 subjects with diabetes
recruited from 9 Kentucky community pharmacies was con-
ducted. Subjects fell into one of three groups: 1) hypothetical
offer followed with certainty calibration; 2) hypothetical offer
preceded by cheap talk; 3) real offer to purchase the service. All
surveys were face-to-face with a trained interviewer. RESULTS:
Before calibration, 45% of subjects in the hypothetical group
stated that they would purchase the service compared to 26% of
subjects in the real group (p = 0.006). After calibration with the
“certainty approach” the difference between the calibrated
(24%) and real response rate was no longer signiﬁcant (p = 0.83).
The cheap talk group had a purchase rate of 45%, which was
signiﬁcantly different from the real group (p = 0.006). CON-
CLUSIONS: This experiment conﬁrms the existence of HB in CV
applications within the HCS. Results suggest that a “certainty-
approach” calibration technique is successful in mitigating HB,
while “cheap talk” script is not.
METHODS
METHODS—Database/Productivity/Risk Management
Studies
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OBJECTIVES: Emergence of retrospective data sources without
diagnosis has necessitated development of methods of assigning
diagnoses using medications as a proxy. The objective of 
this study is to deﬁne a method for this allocation of multi-
indication products using several data sources. METHODS: The
study was conducted using three IMS HEALTH databases:
National Disease and Therapeutic Index (NDTI), a compilation
of the treatment of disease by ofﬁce-based physicians; LifeLink
database, an employer claims database; and LRx, a longitudinal
retail prescription database. Using NDTI, medications com-
monly prescribed for treatment of speciﬁc diseases were identi-
ﬁed. Patients with these drugs and diagnoses separately or in
combination were selected from LifeLinkTM to examine conver-
gence of drug and diagnosis information. Based on the ﬁndings,
a clinical algorithm to allocate prescription use by indication was
designed. RESULTS: Medications used for treatment of asthma
or allergic rhinitis (AR) were identiﬁed using NDTI. When apply-
ing this to LifeLink data, ﬁndings indicated diagnosis alone was
not an adequate means of identifying indication: 49.7% of
patients ﬁlling only asthma medications had only an asthma
diagnosis; 15.0% of those receiving AR medications had a cor-
responding AR diagnosis; and 31.2% had neither diagnosis, yet
ﬁlled prescriptions for both types of medications. Using the infor-
mation gained from this analysis, algorithms were built assign-
ing the most likely diagnosis based on the patient’s drug history.
Using this algorithm in LRx, only 8% of asthma/allergic rhini-
tis prescriptions could not be categorized. Similar patterns were
seen in other therapeutic areas. CONCLUSIONS: Relying on a
single source for deﬁning medications as a proxy for diagnosis
can result in under-identiﬁcation of patients with a condition.
Use of multiple data sources allows for increased accuracy in
identifying drugs or drug combinations used as a proxy for diag-
nosis in a prescription database.
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OBJECTIVES: The growth in the literature documenting rela-
tionships between health and productivity has resulted from the
development of several survey-based productivity measures.
However, some of the survey instruments have been developed
for particular situations and contain idiosyncrasies that make it
difﬁcult to understand whether differences in productivity mea-
sures noted across studies are due to differences in the instru-
ments that were used or the populations to which they were
applied. METHODS: To address this issue, we applied two pro-
ductivity instruments to the same employees working at a large
telecommunications ﬁrm. Productivity metrics obtained from the
Work Productivity Short Inventory and the Work Limitations
Questionnaire were compared. RESULTS: The results suggest
that acute, intermittent, or chronic conditions may reduce pro-
ductivity by 4.9% to 7.1% (or by about $2000 to $2800 per
employee per year), depending on the instrument. CONCLU-
SIONS: While the productivity losses seem comparable, they
suggest different courses of action. The WPSI is designed to point
to particular conditions that seem problematic, while the WLQ
points to the types of productivity problems these or other con-
ditions may elicit. Such problems may reﬂect difﬁculties manag-
ing the time, mental or interpersonal, output, or physical
demands of the job. Given the different foci of these instruments,
the results obtained seem complementary, and both may be
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useful for employers who are interested in estimating productiv-
ity losses and in learning where to focus their energy to help stem
those losses.
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OBJECTIVES: To estimate the prevalence of IBS-D in a US pop-
ulation, and to evaluate patients’ self-reported severity of
episodes. Prior use of medications commonly used to alleviate
IBS symptoms and FS were also evaluated. METHODS: A two-
stage, population based, cross-sectional survey was conducted
from December 2001–February 2002. Data were collected from
U.S. participants via internet panel. Of the 31,829 person sam-
pling frame, 25,986 (82%) completed a screening questionnaire
to identify IBS and subtypes using ROME II criteria. A ques-
tionnaire was administered to IBS-D and alternating IBS (IBS-A)
cases to assess symptoms, medication history, and FS using the
Medical Outcomes Survey SF-36 instrument. RESULTS: Screen-
ing identiﬁed 1713 cases (6.6%) meeting Rome II criteria.
Among these, 1,380 cases had IBS-D (n = 901) and IBS-A (n =
453). A total of 1180 of the 1380 IBS-D and IBS-A cases com-
pleted questionnaires. Between 8–43% of the cases’ most recent
episode were considered severe depending upon various deﬁni-
tions of severity. Over 95% of cases reported taking OTC med-
ications, while 50% used prescription medications to treat IBS
symptoms. Functional status scores of respondents were sub-
stantially lower than national norms on all dimensions of the SF-
36. Individuals reporting their most recent episode as severe had
still further impaired levels of functioning. CONCLUSIONS:
This novel methodology and technology generated population-
based estimates of IBS-D in a short period of time and assisted
a drug sponsor in developing a risk management plan. The pro-
portion of survey respondents deﬁned as severe based on char-
acteristics of their most recent episode is in contrast to estimated
severity rates (~5%) in all IBS subtypes, based on physician
assessments. This is the ﬁrst study to evaluate FS in IBS at the
population level. Using this methodology, additional questions
may be posed to this IBS population.
SESSION II
ASTHMA/ALLERGY (including ARDS)
ASTHMA/ALLERGY (including ARDS)—Clinical
Outcomes Studies
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OBJECTIVE: To measure the impact of an asthma disease man-
agement intervention by comparing pharmacy and in-patient
service utilization during a six-month “pre” and “post” inter-
vention period. METHODS: Care 1st health plan enrollees, pre-
dominantly Medicaid members, were identiﬁed as having asthma
if they had any ER or in-patient claims with ICD-9 codes 493,
or a claim for short acting b2-agonists, or any anti-inﬂammatory
medications in the year prior to the start of the intervention.
Patients were mailed a baseline self-assessment and QoL survey.
Patients were stratiﬁed into four asthma severity categories based
upon claims data; mild-intermittent, mild-persistent, moderate-
persistent, and severe-persistent. Respondents with mild-
intermittent or mild-persistent asthma were enrolled in a
program consisting primarily of educational material delivered
via mail. Respondents and a small number of non-respondents
with moderate-persistent or severe-persistent asthma were
referred to a telephonic case management program. Patients not
responding to the survey, and not enrolled into either of the two
interventions, served as the control group. This analysis is limited
to the 1522 patients with continuous eligibility for the entire
study period, and with at least one pharmacy claim in each of
the two 6-month periods. RESULTS: The mean age of the sample
was 15 years, 47% were female, and 64% were of Hispanic
origin. Overall, the percentage of patients with high b2-agonist
use (4 + claims) decreased from 27.5% in the “pre” to 22.2%
in the “post” period (P < 0.001). Use of oral steroids decreased
from 35% to 28.7%, and inhaled steroids increased from 28.8%
to 33.6% (P < 0.001). Overall percentage of patients with in-
patient hospitalization decreased from 2.6% to 1.1% (P < 0.01).
CONCLUSION: Data from this evaluation provides strong evi-
dence that the comprehensive asthma disease management
program was successful in improving the quality of care provided
to members, and cost-effective due to the observed reduction in
costly inpatient services.
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OBJECTIVES: The aims of this study were to estimate what
portion of asthma patients are using quick-acting asthma med-
ications inappropriately and to examine how the inappropriate
use varies with age and sex. METHODS: Prescribed medicine
data of 1996–2000 from the Medical Expenditure Panel Survey
(MEPS) are retrospectively analyzed. The survey is on-going
project, sponsored by the Agency for Health care Research and
Quality. Non-institutionalized U.S. citizens of 5 or older who had
used quick-acting asthma relievers in a given year were identi-
ﬁed and further classiﬁed as “inappropriate users” if high doses
of short-acting beta-agonists were taken in conjunction with low
doses of inhaled corticosteroids. RESULTS: During the period of
1996–2000, a total of 2390 subjects reported that they had used
quick-acting asthma relievers per year. Of those, 284 (11.88%)
were 65 years of age or older and 862 (36.07%) were ﬁve
through 17 years of age. The remaining 1244 (52.45%) were 18
through 64 years of age. More than half of the subjects were
females (59.21%). About 6 percent (95% CI: 5.07–6.87%) of
the users of quick-acting asthma relievers were using the med-
ication inappropriately. Asthma patients with 65 years of age or
older were subject to a higher risk of medication misuse (9.09 ±
2.32%). Young children with ages of 5 through 17 years were
subject to a lower risk (4.16 ± 0.93%). Although males were
subject to a slightly lower risk than females (95% CI:
4.10–7.87% vs. 5.19–8.80%), the difference was not statistically
signiﬁcant. CONCLUSIONS: Despite the existence of national
guidelines on the proper use of shorting-acting asthma inhalers,
asthma patients who use short-acting asthma inhalers are at a
substantial risk of inappropriate use. Future national policies
should address ways of improving patient compliance in the use
of shorting acting asthma inhalers.
